TEDA BIOMEDICAL (08189) subsidiary Boya Quanjian appeared at China-Hospeq 2025 to empower the human health community with AI intelligence.

From August 15 to August 17, 2025, the 31st China International Medical Equipment Exhibition and Technical Exchange Conference (China-Hospeq) was held at the Beijing National Convention Center. As one of the important activities of the exhibition, on August 16, the "Walking with AI: Health Silk Road AI Empowerment Seminar" hosted by the International Exchange and Cooperation Center of the National Health Commission, Tianjin TEDA BIOMEDICAL Medical Engineering Co., Ltd. (Stock Code: 08189.HK, hereinafter referred to as: TEDA BIOMEDICAL) subsidiary Beijing Boya Quanjian Intelligent Technology Co., Ltd. (referred to as "Boya Quanjian") and co-organized by Peking University Science Park was successfully held. Representatives from the Health Commission of Ningxia Hui Autonomous Region, China Meheco Group Industrial Information Center, CITIC Medical Health Industry Group Limited, and other supporting units gathered at the scene to explore the cutting-edge applications and development of AI technology in the medical field. Focusing on the proposition of optimizing resource allocation and anchoring the strategic direction of AI + medical empowerment The theme of this seminar was "Walking with AI: Health Silk Road AI Empowerment," aiming to use AI technology to build a new "Health Silk Road," break down barriers to medical resources, promote efficient linkage of medical resources between provinces, cities, and rural areas, and internationally, build a wider and more efficient medical service network, allow high-quality medical resources to break through geographical restrictions, and benefit a wider population. The launching ceremony of the "Sino-African Hospital Alliance 'Health Silk Road AI Development' Joint Working Group," the co-construction ceremony of the "Global Children's 'Two Diseases' (Epilepsy, Congenital Heart Disease) Early Diagnosis and Treatment AI Innovation Ecological System," and the signing ceremony of the "Xihe Yi Number" landing in Ningxia to jointly build the DigiHuman management platform were held simultaneously. Many measures injected practical directions into the construction of the "Health Silk Road." By technical cooperation and resource integration, it provides a landing path to break through the geographical barriers of medical resources and improve the accuracy of diagnosis and treatment in urban and rural areas and even internationally, contributing Chinese wisdom and public products to AI medical care for the construction of a global health community. At the same time, the bilingual "Xihe Yi Number" medical large model jointly developed by Peking University Third Hospital, Peking University Institute of Artificial Intelligence, and Boya Quanjian became the focus. The model, developed for nearly 10 years, is based on the research of 1 million real medical records data, forming a 100 billion-level parameter, relying on natural language interaction and traceable knowledge inference dual engines, supporting disease prediction, diagnosis and personalized treatment, image analysis, drug development, clinical trials, medical education, and other scenarios. Applications achieve a medical knowledge coverage rate of 98% and a medical knowledge accuracy rate of over 90%. Building on a foundation of massive clinical data to create a differentiated competitive advantage in precision "Data is the soul of AI models, and the 'Xihe Yi Number' has its soul rooted in the most rigorous clinical medical data." Li Lin, Chairman, Ph.D., and researcher of Beijing Boya Quanjian Intelligent Technology Co., emphasized in an interview, in the increasingly crowded AI medical race, "Xihe Yi Number" establishes a differentiated barrier from the source - using hospital medical records as core training data, using rigorously selected and annotated clinical cases, imaging, and test results as "golden standards" to replace some peers' reliance on second-hand internet information. Li Lin gave an example: "Internet data may contain health information, user questions and answers, but this content lacks clinical validation and may even contain errors. Models trained with internet data are like 'learning to diagnose from books,' while 'Xihe Yi Number' is 'rounds and consultations with doctors at the frontline of clinical care.'" It is reported that the training data of "Xihe Yi Number" comes from the frontline of 18 medical institutions, covering demographic characteristics, temporal physical indicators, imaging, and other multimodal information, with each piece of data undergoing ethical review, desensitization, and annotation by clinical doctors. This data advantage makes the illusion rate of "Xihe Yi Number" very low, with an accuracy rate of over 90%, avoiding fatal errors such as "misdiagnosing a common cough as a serious lung disease" and taking the lead in compliance, clearing the way for subsequent commercialization. In the "AI and Future Medical Vision" segment of the conference, Professor Tang Yida, Associate Dean of the Medical Department of Peking University, Vice President of Peking University Third Hospital, and the chief scientist of the "Xihe Yi Number" large model, shared the application practice of multi-modal large language models in pre-diagnosis and triage in the cardiovascular field. He mentioned that current diseases such as chest pain and heart attacks have a misdiagnosis rate of over 25%, insufficient diagnostic capabilities at the grassroots level, lagging guidelines, high error rates in traditional diagnosis and treatment, examinations taking over 30 minutes, leading to blind medication choices, delays in grassroots treatment increasing the risk of death by 35%. However, "Xihe Yi Number," by constructing a research and development system centered around clinical needs, provides assistance in addressing these issues. In the keynote speech on "AI and the Future of Medical Research," Li Lin said, "Boya Quanjian is committed to building an AI + medical ecosystem covering 'data-model-clinical,' covering multiple areas such as genomics research, medical imaging, drug development, and promoting rapid transformation of scientific research results." She also mentioned that intelligent wheelchairs, nutrition management devices, GUIDiHUMAN health management platform will sign contracts for co-construction in Ningxia to provide better health services matching individuals' needs. In the subsequent roundtable dialogue session, Li Lin, Dean Yao Lan of the School of Medicine, Pharmacy, and Health Management at Tongji Medical College of Huazhong University of Science and Technology, Deputy Director Li Xiuli of the Health Commission of Haidian District, Beijing, and other representatives discussed the core issue of "AI empowering the global medical industry" in-depth, exploring landing paths for construction from multiple perspectives, sparking wisdom and providing diverse ideas for the development of the industry. Deepening the field of AI + medical care TEDA BIOMEDICAL empowers the global digitization of medical care As an enterprise actively involved in domestic medical and health industry innovation, TEDA BIOMEDICAL has always focused on promoting efficient coordination of medical resources, deepening the AI + medical track. Based on its technological accumulation in the biotechnology field, the company has formed a characteristic layout in multiple dimensions: at the clinical application level, focusing on the development of AI medical basic large models, promoting specialist treatment and disease management, improving the efficiency of medical management, and enhancing the research level of hospitals through the construction of a medical data platform; at the resource coordination level, cooperating closely with various levels of domestic medical institutions, scientific research institutes, participating in the structured, standardized, and market-oriented construction of medical big data, forming a strong innovative capability of "technology research and development - scenario landing - industrial empowerment," and deep cooperation with the subsidiary of Xiamen Hongxin Electronics Technology Group Inc. (300657, SZ) in the field of integrated medical diagnosis and treatment machines; at the service application level, actively exploring the "AI + medical" product service model, helping high-quality medical resources extend to counties and towns, providing more convenient and inclusive medical services for grassroots patients. On August 11, 2025, TEDA BIOMEDICAL disclosed an announcement indicating that its holding subsidiary, Shenzhen Yishu Jincheng Technology Co., Ltd., signed a cooperation framework agreement with the Shenzhen Institute of Computational Science. The two parties will integrate their resource advantages to conduct in-depth cooperation in database construction, data quality improvement, and data analysis applications, laying a solid foundation for the iteration and optimization of AI medical large models. "We expect to serve more than 100 million patients within three years." Li Lin said, "More importantly, we will establish a global medical AI collaboration network, working with experts from various countries to improve models and truly achieve global sharing of medical intelligence." The convening of this seminar provides a clearer direction for the development of the industry in the field of AI + medical care. In the future, TEDA BIOMEDICAL will continue to deepen its exploration and practice in the field of AI + medical care, strengthen cooperation with medical institutions, technology companies, industry associations, etc., gather cutting-edge digital intelligence, actively participate in the construction of the "Health Silk Road" ecosystem, and contribute to the optimization of medical resources domestically and internationally, and the improvement of the health levels of the people.